Priced like the old business, running like a new one: management is redirecting the call away from the metric investors
The model's full reasoning — Q1 2022 call → NOThe question asks whether management repeatedly redirects attention away from the conventional yardstick toward a different part of the business that is already earning, and indicates the record hasn't caught up. Let me analyze the transcript. The company is VolitionRx, a diagnostics company. The conventional yardstick would be their human diagnostics business (Nu.Q Cancer, Nu.Q Discover, Nu.Q NETs, Nu.Q Capture). On the call, management discusses: - Financial results (revenue $114k, net loss) - The Heska deal for Nu.Q Vet (veterinary diagnostics) - this is a licensing and supply agreement with milestone payments - SAGE Healthcare launched Nu.Q Vet in Singapore - Tom Butera discusses the veterinary business extensively Does management set aside the conventional yardstick? The conventional yardstick for this company would be the human diagnostics business. Management spends a lot of time on the veterinary business. Cameron says "I'm also delighted with the progress we have made in this key pillar of the business as we progress strongly from a purely research and development company to a commercial company with a wide range of products." But is the veterinary business "already earning"? The Heska deal provides milestone payments - $10 million upfront received, up to $18 million more. But these are milestone payments, not ongoing revenue from sales. The ongoing revenue from kits is expected in the future. The SAGE launch is happening - "SAGE Healthcare launched the Nu.Q Vet Cancer Test in Singapore" - so there is some actual sales activity. Revenue for Q1 was $114k, which included "first sale of our Nu.Q Vet tests to SAGE in Singapore." So the vet business is starting to earn - there are actual sales to SAGE, and the Heska deal has milestone payments. But is management redirecting attention away from the conventional yardstick? The conventional yardstick for VolitionRx would be their human diagnostics pipeline (Nu.Q Cancer, NETs, etc.). Management does spend a lot of time on the vet business. But do they explicitly set aside the conventional yardstick? Looking at the call, management discusses all the pillars. Cameron says "Our next key element of the Company is our product. We have five product pillars, one of which Tom covered earlier with regards to Nu.Q Vets." Then he briefly updates on Nu.Q Cancer, Nu.Q Discover, Nu.Q NETs, Nu.Q Capture.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| LOB | Live Oak Bancshares, Inc. | Q3 2018 | 2018-10-25 | C+ |
SPT · Q2 2023 → YESThe question is whether management repeatedly redirects attention away from the conventional measure toward a different part of the business that's already earning today, and indicates that this diffe...YES The transcript shows management repeatedly reframing away from the conventional total ARR/revenue growth metric (which is being distorted by unpredictable low-end non-core ARR) toward the higher-quality up-market/enterprise segment that is already delivering record new business ACVs, 50%+ YoY growth, and 43% of 2023 ARR. They explicitly set the low-end aside by removing it from forecasts and modeling to give “greatest visibility,” note that Q2 ARR growth will be the lowest pace of the year because of this change, and indicate the reported figures still reflect the old mix while the new up-market story is already earning today (with Tagger adding further upside not yet reflected). This creates the coherent posture of redirecting attention from the headline growth number outsiders watch to the part of the business that is already producing real results.
WD · Q2 2022 → YESThe question is about whether management repeatedly redirects attention away from the conventional measure to a different part of the business that's already earning today, and indicates that this isn...YES The transcript shows management repeatedly reframing the discussion away from the conventional multifamily agency lender yardstick (origination volumes, GSE lending, MSR-driven EPS) toward the diversified services and asset-management businesses that are already generating substantial cash revenue and EBITDA today. They explicitly set the old metric aside by introducing adjusted EPS to “strip out non-cash mortgage servicing rights,” highlight the shift from “lending-centric” to “broader technology-enabled financial services,” and note that segment results now provide “more transparency into our operating structure.” They point to debt brokerage, property sales, SAM (Alliant, Zelman), small-balance lending, and appraisals as the new earning engines, describing their concrete contributions (e.g.
CALX · Q1 2023 → YESThe question is about whether management repeatedly redirects attention away from the conventional measure to a different part of the business that's already earning today, and indicates that this isn...YES The transcript shows management repeatedly framing the company as operating in a "new market" centered on platforms, clouds, and managed services—distinct from the legacy hardware/cyclical model—while highlighting real earnings from these areas (e.g., 988 BSPs deploying platforms, 865 cloud customers, 334 with 41 new managed services in Q1, record Intelligent Access EDGE revenue). They indicate this is already producing revenue and customer adoption but remains early-stage ("this is the beginning," "early stage of where we are in this new market"), with reported results still reflecting the prior hardware-focused picture.